Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway

Paolo Gubellini, Diego Centonze, Domenicantonio Tropepi, Giorgio Bernardi, Paolo Calabresi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder typically affecting individuals in midlife. HD is characterized by the selective loss of striatal spiny neurons, while large cholinergic interneurons are spared. An impaired mitochondrial complex II (succinate dehydrogenase, SD) activity is known as a prominent metabolic alteration in HD. Accordingly, chronic treatment with 3-nitropropionic acid (3-NP), an irreversible SD inhibitor, mimics motor abnormalities and pathology of HD in several animal models. We have previously shown that in vitro application of 3-NP induces a long-term potentiation (LTP) of corticostriatal synaptic transmission through NMDA glutamate receptor. Since this 3-NP-induced LTP (3-NP-LTP) is shown by striatal spiny neurons, but not by cholinergic interneurons, it might play a role in the regional and cell type-specific neuronal death observed in HD. Here we investigate the role of group I metabotropic glutamate receptors (mGluRs) in the induction of 3-NP-LTP. We report that selectively blocking mGluR1, but not mGluR5, suppresses 3-NP-LTP induction. Moreover, we show that a PKC-mediated mechanism is involved in the formation of 3-NP-LTP. Characterizing the cellular mechanisms underlying 3-NP-LTP may provide new insights to better understand the processes leading to the selective neuronal loss observed in HD.

Original languageEnglish
Pages (from-to)761-769
Number of pages9
JournalNeuropharmacology
Volume46
Issue number6
DOIs
Publication statusPublished - May 2004

Fingerprint

Long-Term Potentiation
Huntington Disease
Corpus Striatum
Succinate Dehydrogenase
Interneurons
Metabotropic Glutamate Receptors
Cholinergic Neurons
Glutamate Receptors
3-nitropropionic acid
metabotropic glutamate receptor type 1
N-Methyl-D-Aspartate Receptors
Synaptic Transmission
Neurodegenerative Diseases
Cholinergic Agents
Animal Models
Pathology
Neurons

Keywords

  • Electrophysiology
  • Glutamate
  • Huntington's disease
  • LY 367385
  • MPEP
  • Succinate dehydrogenase
  • Synaptic plasticity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. / Gubellini, Paolo; Centonze, Diego; Tropepi, Domenicantonio; Bernardi, Giorgio; Calabresi, Paolo.

In: Neuropharmacology, Vol. 46, No. 6, 05.2004, p. 761-769.

Research output: Contribution to journalArticle

Gubellini, Paolo ; Centonze, Diego ; Tropepi, Domenicantonio ; Bernardi, Giorgio ; Calabresi, Paolo. / Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. In: Neuropharmacology. 2004 ; Vol. 46, No. 6. pp. 761-769.
@article{caa3fc6e5fcf4807b36fbe5d2c4925b1,
title = "Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway",
abstract = "Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder typically affecting individuals in midlife. HD is characterized by the selective loss of striatal spiny neurons, while large cholinergic interneurons are spared. An impaired mitochondrial complex II (succinate dehydrogenase, SD) activity is known as a prominent metabolic alteration in HD. Accordingly, chronic treatment with 3-nitropropionic acid (3-NP), an irreversible SD inhibitor, mimics motor abnormalities and pathology of HD in several animal models. We have previously shown that in vitro application of 3-NP induces a long-term potentiation (LTP) of corticostriatal synaptic transmission through NMDA glutamate receptor. Since this 3-NP-induced LTP (3-NP-LTP) is shown by striatal spiny neurons, but not by cholinergic interneurons, it might play a role in the regional and cell type-specific neuronal death observed in HD. Here we investigate the role of group I metabotropic glutamate receptors (mGluRs) in the induction of 3-NP-LTP. We report that selectively blocking mGluR1, but not mGluR5, suppresses 3-NP-LTP induction. Moreover, we show that a PKC-mediated mechanism is involved in the formation of 3-NP-LTP. Characterizing the cellular mechanisms underlying 3-NP-LTP may provide new insights to better understand the processes leading to the selective neuronal loss observed in HD.",
keywords = "Electrophysiology, Glutamate, Huntington's disease, LY 367385, MPEP, Succinate dehydrogenase, Synaptic plasticity",
author = "Paolo Gubellini and Diego Centonze and Domenicantonio Tropepi and Giorgio Bernardi and Paolo Calabresi",
year = "2004",
month = "5",
doi = "10.1016/j.neuropharm.2003.11.021",
language = "English",
volume = "46",
pages = "761--769",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway

AU - Gubellini, Paolo

AU - Centonze, Diego

AU - Tropepi, Domenicantonio

AU - Bernardi, Giorgio

AU - Calabresi, Paolo

PY - 2004/5

Y1 - 2004/5

N2 - Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder typically affecting individuals in midlife. HD is characterized by the selective loss of striatal spiny neurons, while large cholinergic interneurons are spared. An impaired mitochondrial complex II (succinate dehydrogenase, SD) activity is known as a prominent metabolic alteration in HD. Accordingly, chronic treatment with 3-nitropropionic acid (3-NP), an irreversible SD inhibitor, mimics motor abnormalities and pathology of HD in several animal models. We have previously shown that in vitro application of 3-NP induces a long-term potentiation (LTP) of corticostriatal synaptic transmission through NMDA glutamate receptor. Since this 3-NP-induced LTP (3-NP-LTP) is shown by striatal spiny neurons, but not by cholinergic interneurons, it might play a role in the regional and cell type-specific neuronal death observed in HD. Here we investigate the role of group I metabotropic glutamate receptors (mGluRs) in the induction of 3-NP-LTP. We report that selectively blocking mGluR1, but not mGluR5, suppresses 3-NP-LTP induction. Moreover, we show that a PKC-mediated mechanism is involved in the formation of 3-NP-LTP. Characterizing the cellular mechanisms underlying 3-NP-LTP may provide new insights to better understand the processes leading to the selective neuronal loss observed in HD.

AB - Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder typically affecting individuals in midlife. HD is characterized by the selective loss of striatal spiny neurons, while large cholinergic interneurons are spared. An impaired mitochondrial complex II (succinate dehydrogenase, SD) activity is known as a prominent metabolic alteration in HD. Accordingly, chronic treatment with 3-nitropropionic acid (3-NP), an irreversible SD inhibitor, mimics motor abnormalities and pathology of HD in several animal models. We have previously shown that in vitro application of 3-NP induces a long-term potentiation (LTP) of corticostriatal synaptic transmission through NMDA glutamate receptor. Since this 3-NP-induced LTP (3-NP-LTP) is shown by striatal spiny neurons, but not by cholinergic interneurons, it might play a role in the regional and cell type-specific neuronal death observed in HD. Here we investigate the role of group I metabotropic glutamate receptors (mGluRs) in the induction of 3-NP-LTP. We report that selectively blocking mGluR1, but not mGluR5, suppresses 3-NP-LTP induction. Moreover, we show that a PKC-mediated mechanism is involved in the formation of 3-NP-LTP. Characterizing the cellular mechanisms underlying 3-NP-LTP may provide new insights to better understand the processes leading to the selective neuronal loss observed in HD.

KW - Electrophysiology

KW - Glutamate

KW - Huntington's disease

KW - LY 367385

KW - MPEP

KW - Succinate dehydrogenase

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=1642277124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642277124&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2003.11.021

DO - 10.1016/j.neuropharm.2003.11.021

M3 - Article

C2 - 15033336

AN - SCOPUS:1642277124

VL - 46

SP - 761

EP - 769

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 6

ER -